NCT07085559View on ClinicalTrials.gov

Safety and Efficacy of Metabolically Armed BCMA CAR-T Cells (Meta10-BCMA) in the Treatment of r/r Plasma Cell Neoplasms Clinical Research

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

June 23, 2025

Primary Completion Date

June 30, 2027

Study Completion Date

October 15, 2027

Conditions
Multiple Myeloma (MM)Plasma Cell Leukemia (PCL)AL Amyloidosis (AL)
Interventions
DRUG

Metabolically Armed BCMA CAR-T cells.

Each subject receive metabolically armed BCMA CAR- T cells by intravenous infusion.

Trial Locations (1)

Unknown

RECRUITING

Anhui Provincial Hospital, Hefei

Sponsors

Collaborators (1)

Leman Biotech Co., Ltd.
All Listed Sponsors
collaborator

Leman Biotech Co., Ltd.

INDUSTRY

lead

Anhui Provincial Hospital

OTHER_GOV